RANITIDINE HYDROCHLORIDE- ranitidine hydrochloride tablet, film coated

国: アメリカ合衆国

言語: 英語

ソース: NLM (National Library of Medicine)

有効成分:

RANITIDINE HYDROCHLORIDE (UNII: BK76465IHM) (RANITIDINE - UNII:884KT10YB7)

から入手可能:

Mylan Institutional Inc.

INN（国際名）:

RANITIDINE HYDROCHLORIDE

構図:

RANITIDINE 150 mg

投与経路:

ORAL

処方タイプ:

PRESCRIPTION DRUG

適応症:

Ranitidine is indicated in: Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis. Ranitidine is contraindicated in patients known to have hypersensitivity to the drug or any of the ingredients (see PRECAUTIONS ).

製品概要:

Ranitidine Tablets, USP for oral administration, are available as: 150 mg: round, off-white, unscored tablets, film-coated pink, debossed GG 705 on one side and plain on the reverse side and supplied as: NDC 51079-879-20 – Unit dose blister packages of 100 (10 cards of 10 tablets each). Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Store in a dry place and protect from light. Manufactured by: Sandoz Inc. Princeton, NJ 08540 Distributed by: Mylan Institutional Inc. Rockford, IL 61103 U.S.A. S-10341 R5 10/14

認証ステータス:

Abbreviated New Drug Application

製品の特徴

RANITIDINE HYDROCHLORIDE- RANITIDINE HYDROCHLORIDE TABLET, FILM COATED
MYLAN INSTITUTIONAL INC.
----------
RANITIDINE TABLETS, USP AND RANITIDINE CAPSULES
DESCRIPTION
Ranitidine hydrochloride (HCl), is a histamine H -receptor antagonist.
Chemically it is _N_-[2-[[[5-
[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-_N’_-methyl-2-nitro-1,1-ethenediamine,
HCl.
It has the following structure:
The empirical formula is C
H N O S • HCl, representing a molecular weight of 350.87.
Ranitidine HCl is a white to pale yellow, granular substance that is
soluble in water. It has a slightly
bitter taste and sulfur like odor.
Each tablet, for oral administration contains 168 mg or 336 mg of
ranitidine hydrochloride equivalent to
150 mg and 300 mg of ranitidine, respectively. Inactive ingredients: D
& C Red #30 Aluminum Lake,
hydroxypropyl cellulose, hydroxypropyl methylcellulose, magnesium
stearate, microcrystalline
cellulose, triethyl citrate, sodium starch glycolate, titanium dioxide
and flavoring. The 300 MG also
contains: D & C Yellow #10 Aluminum Lake.
Each capsule, for oral administration contains 168 mg or 336 mg of
ranitidine hydrochloride equivalent
to 150 mg and 300 mg of ranitidine, respectively. Inactive
ingredients: Ammonium hydroxide, colloidal
silicon dioxide, corn starch, FD & C Blue #1, FD & C Red #40, FD & C
Yellow #6, gelatin,
magnesium stearate, pharmaceutical glaze, propylene glycol, silicon
dioxide, simethicone, sodium
lauryl sulfate, sodium starch glycolate, and titanium dioxide.
CLINICAL PHARMACOLOGY
Ranitidine is a competitive, reversible inhibitor of the action of
histamine at the histamine H -receptors,
including receptors on the gastric cells. Ranitidine does not lower
serum Ca++ in hypercalcemic states.
Ranitidine is not a anticholinergic agent.
PHARMACOKINETICS
Absorption
Ranitidine tablets and ranitidine capsules are 50% absorbed after oral
administration, compared to an
intravenous (IV) injection with mean peak levels of 440 to 545 ng/mL
occurring 2 to 3 hours after a 150
mg dose. Absorpti